17432-95-0

Basic information

• Product Name: 5-isopropyluracil
• Synonyms: 5-Isopropyluracil; NSC 149002; 2,4(1H,3H)-Pyrimidinedione, 5-(1-methylethyl)-; 5-(propan-2-yl)pyrimidine-2,4(1H,3H)-dione
• CAS NO: 17432-95-0
• Molecular Formula: C₇H₁₀N₂O₂
• Molecular Weight: 154.1665
• Mol File: 17432-95-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.142g/cm³
• Refractive Index: 1.487
• CAS DataBase Reference: 5-isopropyluracil(CAS DataBase Reference)
• NIST Chemistry Reference: 5-isopropyluracil(17432-95-0)
• EPA Substance Registry System: 5-isopropyluracil(17432-95-0)

Safety Data

• Hazardous Substances Data: 17432-95-0(Hazardous Substances Data)

Usage

General Description

5-Isopropyluracil, also known as IPU, is a chemical compound that is commonly used in the pharmaceutical industry. It belongs to the class of pyrimidines and is a synthetic derivative of uracil. IPU is used in the treatment of various skin conditions, including psoriasis, vitiligo, and alopecia areata. It works by stimulating the growth of skin cells and promoting the regeneration of hair follicles. Additionally, IPU has been found to have immunomodulatory and anti-inflammatory properties, making it a versatile and effective ingredient in the development of topical medications for skin disorders. Despite its beneficial effects, IPU should be used with caution and under the guidance of a healthcare professional to minimize potential side effects.

InChI:InChI=1/C7H10N2O2/c1-4(2)5-3-8-7(11)9-6(5)10/h3-4H,1-2H3,(H2,8,9,10,11)

Upstream product

• 108-64-5 Ethyl isovalerate 
• 109-94-4 formic acid ethyl ester 
• 556-24-1 methyl 3-methylbutanoate 
• 96796-80-4 5-isopropyl-6-chloro-2,4-pyrimidinedione 
• 18718-34-8 5-isopropyl-2-thiouracil 
• 7391-69-7 5-isopropylbarbituric acid 

Downstream Products

• 60136-25-6 2'-deoxy-β-D-ribofuranoside of 5-i-propyluracil 
• 76540-23-3 2'-deoxy-3',5'-di-O-(p-tolyl)-β-D-ribofuranoside of 5-i-propyluracil 
• 76549-87-6 2'-deoxy-3',5'-di-O-(p-tolyl)-α-D-ribofuranoside of 5-i-propyluracil 
• 1352571-48-2 2-(3-isopropoxy-5-(4-(methylsulfonyl)phenoxy)phenyl)-5-isopropyl-4-(4-methoxybenzyloxy)pyrimidine 
• 1352570-43-4 2-(3-isopropoxy-5-(4-(methylsulfonyl)phenoxy)phenyl)-5-isopropylpyrimidin-4(3H)-one 
• 1352571-33-5 2-chloro-5-isopropyl-4-(4-methoxybenzyloxy)pyrimidine 
• 99097-07-1 1-(3-O-acetyl-5-O-benzoyl-2-deoxy-2-fluoro-D-arabinofuranosyl)-5-isopropyluracil 
• 175470-85-6 1-((2R,4S,5R)-4-Benzyloxy-5-benzyloxymethyl-tetrahydro-thiophen-2-yl)-5-isopropyl-1H-pyrimidine-2,4-dione 
• 1026863-23-9 1-[2-(tert-Butyl-dimethyl-silanyloxy)-ethoxymethyl]-6-(3,5-dimethyl-phenylselanyl)-5-isopropyl-1H-pyrimidine-2,4-dione 
• 1026694-92-7 1-[2-(tert-Butyl-dimethyl-silanyloxy)-ethoxymethyl]-5-isopropyl-6-m-tolylselanyl-1H-pyrimidine-2,4-dione 
• 1026536-28-6 1-[2-(tert-Butyl-dimethyl-silanyloxy)-ethoxymethyl]-5-isopropyl-6-phenylselanyl-1H-pyrimidine-2,4-dione 
• 172255-88-8 6-[(3,5-dimethylphenyl)selenenyl]-1-[(2-hydroxyethoxy)methyl]-5-isopropyluracil 
• 172255-87-7 1-[(2-hydroxyethoxy)methyl]-5-isopropyl-6-[(3-methylphenyl)-selenenyl]uracil 
• 172255-86-6 1-[(2-hydroxyethoxy)methyl]-5-isopropyl-6-(phenylselenenyl)-uracil 

Relevant articles and documents

NOVEL COMPOUNDS AND THEIR USES AS THYROID HORMONE RECEPTOR AGONISTS

A compound of formula (I) or (Ia), or a tautomer or a pharmaceutically acceptable salt thereof is provided. Compounds of formula (II) to (V), or a tautomer or a pharmaceutically acceptable salt thereof are also provided. These compounds and the pharmaceutical compositions containing them are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto． (I), (Ia)

Method for producing 5-isopropyluracil

A method for producing 5-isopropyluracil at a high yield in a short time, wherein N-(2-cyano-3-methylbutanoyl)urea is reduced in a 10-15% aqueous sulfuric acid solution in the presence of palladium carbon at 30-45° C., heated for ring closure reaction and added to a 50-70% aqueous sulfuric acid solution to give 5-isopropyluracil having a high purity.

Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives as alpha-1-adrenergic receptor antagonists

The present invention relates to novel α1-adrenoceptor antagonists of the formula I*(formula 01)* in which: R1 is acetylamino, amino, cyano, trifluoroacetylamino, halo, hydro, hydroxy, nitro, methylsulfonylamino, 2-propynyloxy, a group selected from (C1-6)alkyl, (C3-6)cycloalkyl, (C3-6)cycloalkyl(C1-4)alkyl, (C1-6)alkyloxy, (C3-6)cycloalkyloxy, (C3-6)cycloalkyl(C1-4)alkyloxy and (C1-4)alkylthio (which group is optionally further substituted with one to three halo atoms) or a group selected from aryl, aryl(C1-4)alkyl, heteroaryl, heteroaryl(C1-4)alkyl, aryloxy, aryl(C1-4)alkyloxy, heteroaryloxy and heteroaryl(C1-4)alkyloxy (which aryl and heteroaryl are optionally further substituted with one to two radicals independently selected from halo and cyano); R2 is cyano, halo, hydro, hydroxy or a group selected from (C1-6)alkyl and (C1-6)alkyloxy (which group is optionally further substituted with one to three halogen atoms);R3 and R4 are both hydro or methyl or together are ethylene; and R5 is a group selected from Formulae (a), (b), (c) and (d):*(formula 02)* in which: X is C(O), CH2 or CH(OH); Y is CH2 or CH(OH); Z is N or C(R9), wherein R9 is hydro, (C1-6)alkyl or hydroxy; R6 is hydro, a group selected from (C1-6)alkyl, (C3-6)cycloalkyl, (C3-6)cycloalkyl(C1-4)alkyl (which group is optionally further substituted with one to three halo atoms) or a group selected from aryl, heteroaryl, aryl(C1-4)alkyl and heteroaryl(C1-4)alkyl (which aryl and heteroaryl are optionally further substituted with one to three radicals selected from halo, cyano, (C1-6)alkyloxy, (C1-6)alkyl and aryl); R7 is (C1-6)alkanoyl, carbamoyl, cyano, di(C1-6)alkylamino, halo, hydro, hydroxy, hydroxyiminomethyl, (C1-6)alkylsulfonyl, (C1-6)alkylthio, a group selected from (C1-6)alkyl, (C3-6)cycloalkyl,(C1-6)alkyloxy and (C1-6)alkyloxy(C1-4)alkyl (which group is optionally further substituted with one to three radicals selected from halo, hydroxy or (C1-6)alkyloxy) or a group selected from aryl, heteroaryl, aryl(C1-4)alkyl and heteroaryl(C1-4)alkyl (which aryl and heteroaryl are optionally further substituted with one to three radicals selected from halo, cyano, (C1-6)alkyloxy, (C1-6)alkyl and aryl) or R7 and R9 together are tetramethylene; and each R8 is independently hydro, hydroxy, methyl or ethyl; and the pharmaceutically acceptable salts and N-oxides thereof.